TNFRSF17, encoding for the B-Cell Maturation Antigen (BCMA), is currently being actively investigated as a potential therapeutic target in hematological malignancies such as multiple myeloma [55,56,57,58]. This evidence concerns the gene PPIB and plasma cell myeloma.